2025 Q4 -tulosraportti
Vain PDF
56 päivää sitten
Tarjoustasot
First North Denmark
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 330 | - | - | ||
| 3 000 | - | - | ||
| 2 582 | - | - | ||
| 948 | - | - | ||
| 30 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 32 424 | 32 424 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 32 424 | 32 424 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·14 t sittenWill it positively affect stenocare that American cannabis stocks are currently rising a lot?
·1 t sitten · MuokattuI don't think so. I would say that it depends on how Stenocare's earnings will be in Germany. The more earnings, the higher the share price. Roughly speaking. To something completely different. First, I just want to say that the German health insurance system is completely bonkers. I coincidentally stumbled upon the fact that there have been changes in their health insurance system in April 2024. These changes are beneficial for the Astrum 10-10 oil. It is incredibly complicated, so the explanation is broadly speaking. Because Astrum 10-10 has a 100% reimbursement approval, it will be easier for the doctor to get permission to prescribe a prescription that will be approved faster than if there is no reimbursement approval. Because Astrum 10-10 has a reimbursement approval, the application does not automatically get fast processing, but the doctor must request it themselves. But for products that do not have any reimbursement approval, it will be almost impossible for the doctor to get fast processing, nor to be allowed to prescribe a prescription. Fast processing when a product meets the above. For terminally ill patients, the doctor can give the prescription to their patients immediately, without the application having to be submitted first. For very ill patients, the doctor can give a prescription to their patients, in 3 days. For all others, it is up to 3 weeks, that is when the doctor assesses that it is urgent for their patients, but they are not terminally ill. Stenocare has stated that the two partners are in full swing teaching the doctors in their network how to fill out an application when it comes to Astrum 10-10, because this is a very complicated process. They have been doing this since 2024. As I wrote, a completely bonkers system.- ·2 päivää sitten · MuokattuBecause blueoceanguy very aggressively attacks Stenocare and has made claims that Stenocare as a company has no business in Germany, and that they will not make money in Germany, I set out to find articles, or something similar, that would show that Stenocare as a company will indeed make a lot of money in the German market. It has not been a straightforward path; it was very complicated. I found that the German system is completely different from the Danish one, and that the way the German system is structured will actually be an advantage for Stenocare's earnings. What I have found out, I share below, which you can read if it interests you. For clarity, I have put it in bullet points. 1. Astrum 10-10 is approved for 100% reimbursement by two insurance companies (Techniker Krankenkasse and AOK Rheinland, which together have about 14 million members) where the medicine will be free, but in Germany, one apparently pays a prescription fee, from 30-75kr. per prescription. As long as there is 100% reimbursement, and a person has started using Astrum 10-10, and it works as it should, it will be rare for people to switch to another brand. This will provide continuous sales of Astrum 10-10 2. In Germany, public reimbursement is called reimbursement, and this reimbursement will be the primary reason why Astrum 10-10 will become very valuable for Stenocare's earnings. 3. Doctors in Germany are more inclined to prescribe medicine with the highest subsidy than medicine with less than 100% subsidy, because doctors want to ensure that their patients can afford to buy the medicine. 4. But in Germany, doctors have a fixed budget for each quarter for medicine they prescribe to their patients, and which they must adhere to. If doctors only prescribe the most expensive medicine, that is, only medicine that insurance companies have not approved for reimbursement, which would cause doctors to exceed the fixed budget, then the doctors themselves will have to pay the difference out of their own pocket to the public. Astrum 10-10 is approved for 100% reimbursement, so prescribing Astrum 10-10 to their patients will not affect the doctors' budget. This also means that Astrum 10-10 is not price-sensitive in Germany, compared to a product that is not approved for 100% reimbursement. 5. German doctors also consider whether the medicine they prescribe has a positive effect on their patients, and whether the medicine's content complies with what is stated on the label, but also look at whether there is reimbursement, for the reasons mentioned above. 6. In Germany, doctors must write an application for their patients the first time they want to prescribe medicine that is reimbursed. This can be complicated, so Weeco is busy teaching doctors how to correctly write the application. This process also means that doctors will not be keen for their patients to switch to another brand. This is a significant reason why Astrum 10-10 will have a stable income in Germany once the market is saturated. 7. Finally, Germany is considered a growth market, see link below Explanation of telemedical service. At the time of writing, one must appear in person for the first prescription, subsequently within 12 mths., one can call the doctor and get a prescription, and it is forbidden to send flower medicine by post, but pharmacies are allowed to send cannabis oil by post. This point is not yet clarified in Germany. When Stenocare claims that Astrum 10-10 will become very valuable for Stenocare's earnings, I believe that is absolutely correct. Germany is considered a growth market for prescription medical cannabis https://businessofcannabis.com/new-report-uk-and-germany-medical-cannabis-markets-both-double-in-2025/·23 t sittenHm, you yourself have Stenocare, so I think that you have followed along, and therefore are aware that they have had an operating profit for the last 3 quarters. That in 2026 they have two partners in Germany, who have more than 7000 doctors in their network. That both partners are connected to the German distribution platform, which all 18,000 pharmacies use to order medicine. I think there is substance in it, when Stenocare's management has an optimistic attitude towards sales in Germany. Now, it is a management that is very conservative, and therefore you don't get more out of them than that they are optimistic. In addition to this, I have remembered that last year, they divested the cultivation facilities, and the expenses for this are over, as well as the expense that has been for winding these down, will be a one-off expense, therefore these expenses are over, and for all future. This also means that Stenocare stands much stronger now, financially, than when they had the aforementioned expenses. Praise, I would not call it that. Realism I would rather call it.
·20 t sittenAt the current stage, it is nothing but praise - that is a fact. And trust me: We know Weeco quite well, and they are a minnow player in the German market. They buy and try to sell all sorts of crap from various distributors they can get in touch with. It is not a partner that moves the needle commercially - it is a partner that at best gives STENOCARE a foot in the door, and at worst fills warehouse shelves without real off-take in the pharmacy channel. So when "strategic partnership" and similar are mentioned in press releases, one should read it with those glasses: it is distribution on trial, not a guarantee of revenue. And until the opposite is proven, this is merely praise and hot air – nothing else. - ·17.4.I am starting a new thread. I wrote a post as a continuation of another one a little while ago, But it got lost. Astrum 10-10 is being sold through Weecos' network in Germany. Sales started on February 1, 2026. Therefore, we cannot yet see the sales from there in the financial statements. Stenocare sells through its partner Weeco, who uses its network. The doctors are still in the training period, which is an advantage for Stenocare, because their product Astrum 10-10 is included in the first wave. My expectations for the doctors in Germany are that they will welcome Astrum 10-10, because the medicine meets all the requirements that doctors have continuously made for medical cannabis, if they are to prescribe prescriptions; these requirements continuously emerged in various articles before Germany released medical cannabis. I have listed these requirements in bullet points, and Stenocare can tick off all the requirements, because Astrum 10-10 meets them all 1. The medicine must have the strength stated on the label in all batches. 2. It must work within the time the manufacturer promises 3. It must meet the strict requirements that Germany demands 4. It must be approved by their insurance companies 5. That there is reimbursement for the medicine 6. That doctors can count on a consistent absorption every time. Therefore, my expectations are that Astrum 10-10 will perform well in Germany, as doctors are trained in the product.·17.4.Germany is irrelevant for StenoCare.
- ·16.4.The USA is further ahead than Europe regarding research into medical cannabis, etc. Therefore, I also find articles about research over there. Researchers have found out. that CBD is better to use as sleep medicine, because people fall asleep and dream. It is commonly known that traditional sleep medicine deprives people of their dreams, which causes some bad side effects. Sleep problems are also a phenomenon outside the USA, personally I know several, and who use CBD oil to fall asleep, they have the same good experience. https://www.nugmag.com/cbd-for-better-sleep-discovering-its-powerful-effects/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
56 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·14 t sittenWill it positively affect stenocare that American cannabis stocks are currently rising a lot?·1 t sitten · MuokattuI don't think so. I would say that it depends on how Stenocare's earnings will be in Germany. The more earnings, the higher the share price. Roughly speaking. To something completely different. First, I just want to say that the German health insurance system is completely bonkers. I coincidentally stumbled upon the fact that there have been changes in their health insurance system in April 2024. These changes are beneficial for the Astrum 10-10 oil. It is incredibly complicated, so the explanation is broadly speaking. Because Astrum 10-10 has a 100% reimbursement approval, it will be easier for the doctor to get permission to prescribe a prescription that will be approved faster than if there is no reimbursement approval. Because Astrum 10-10 has a reimbursement approval, the application does not automatically get fast processing, but the doctor must request it themselves. But for products that do not have any reimbursement approval, it will be almost impossible for the doctor to get fast processing, nor to be allowed to prescribe a prescription. Fast processing when a product meets the above. For terminally ill patients, the doctor can give the prescription to their patients immediately, without the application having to be submitted first. For very ill patients, the doctor can give a prescription to their patients, in 3 days. For all others, it is up to 3 weeks, that is when the doctor assesses that it is urgent for their patients, but they are not terminally ill. Stenocare has stated that the two partners are in full swing teaching the doctors in their network how to fill out an application when it comes to Astrum 10-10, because this is a very complicated process. They have been doing this since 2024. As I wrote, a completely bonkers system.
- ·2 päivää sitten · MuokattuBecause blueoceanguy very aggressively attacks Stenocare and has made claims that Stenocare as a company has no business in Germany, and that they will not make money in Germany, I set out to find articles, or something similar, that would show that Stenocare as a company will indeed make a lot of money in the German market. It has not been a straightforward path; it was very complicated. I found that the German system is completely different from the Danish one, and that the way the German system is structured will actually be an advantage for Stenocare's earnings. What I have found out, I share below, which you can read if it interests you. For clarity, I have put it in bullet points. 1. Astrum 10-10 is approved for 100% reimbursement by two insurance companies (Techniker Krankenkasse and AOK Rheinland, which together have about 14 million members) where the medicine will be free, but in Germany, one apparently pays a prescription fee, from 30-75kr. per prescription. As long as there is 100% reimbursement, and a person has started using Astrum 10-10, and it works as it should, it will be rare for people to switch to another brand. This will provide continuous sales of Astrum 10-10 2. In Germany, public reimbursement is called reimbursement, and this reimbursement will be the primary reason why Astrum 10-10 will become very valuable for Stenocare's earnings. 3. Doctors in Germany are more inclined to prescribe medicine with the highest subsidy than medicine with less than 100% subsidy, because doctors want to ensure that their patients can afford to buy the medicine. 4. But in Germany, doctors have a fixed budget for each quarter for medicine they prescribe to their patients, and which they must adhere to. If doctors only prescribe the most expensive medicine, that is, only medicine that insurance companies have not approved for reimbursement, which would cause doctors to exceed the fixed budget, then the doctors themselves will have to pay the difference out of their own pocket to the public. Astrum 10-10 is approved for 100% reimbursement, so prescribing Astrum 10-10 to their patients will not affect the doctors' budget. This also means that Astrum 10-10 is not price-sensitive in Germany, compared to a product that is not approved for 100% reimbursement. 5. German doctors also consider whether the medicine they prescribe has a positive effect on their patients, and whether the medicine's content complies with what is stated on the label, but also look at whether there is reimbursement, for the reasons mentioned above. 6. In Germany, doctors must write an application for their patients the first time they want to prescribe medicine that is reimbursed. This can be complicated, so Weeco is busy teaching doctors how to correctly write the application. This process also means that doctors will not be keen for their patients to switch to another brand. This is a significant reason why Astrum 10-10 will have a stable income in Germany once the market is saturated. 7. Finally, Germany is considered a growth market, see link below Explanation of telemedical service. At the time of writing, one must appear in person for the first prescription, subsequently within 12 mths., one can call the doctor and get a prescription, and it is forbidden to send flower medicine by post, but pharmacies are allowed to send cannabis oil by post. This point is not yet clarified in Germany. When Stenocare claims that Astrum 10-10 will become very valuable for Stenocare's earnings, I believe that is absolutely correct. Germany is considered a growth market for prescription medical cannabis https://businessofcannabis.com/new-report-uk-and-germany-medical-cannabis-markets-both-double-in-2025/·23 t sittenHm, you yourself have Stenocare, so I think that you have followed along, and therefore are aware that they have had an operating profit for the last 3 quarters. That in 2026 they have two partners in Germany, who have more than 7000 doctors in their network. That both partners are connected to the German distribution platform, which all 18,000 pharmacies use to order medicine. I think there is substance in it, when Stenocare's management has an optimistic attitude towards sales in Germany. Now, it is a management that is very conservative, and therefore you don't get more out of them than that they are optimistic. In addition to this, I have remembered that last year, they divested the cultivation facilities, and the expenses for this are over, as well as the expense that has been for winding these down, will be a one-off expense, therefore these expenses are over, and for all future. This also means that Stenocare stands much stronger now, financially, than when they had the aforementioned expenses. Praise, I would not call it that. Realism I would rather call it.·20 t sittenAt the current stage, it is nothing but praise - that is a fact. And trust me: We know Weeco quite well, and they are a minnow player in the German market. They buy and try to sell all sorts of crap from various distributors they can get in touch with. It is not a partner that moves the needle commercially - it is a partner that at best gives STENOCARE a foot in the door, and at worst fills warehouse shelves without real off-take in the pharmacy channel. So when "strategic partnership" and similar are mentioned in press releases, one should read it with those glasses: it is distribution on trial, not a guarantee of revenue. And until the opposite is proven, this is merely praise and hot air – nothing else.
- ·17.4.I am starting a new thread. I wrote a post as a continuation of another one a little while ago, But it got lost. Astrum 10-10 is being sold through Weecos' network in Germany. Sales started on February 1, 2026. Therefore, we cannot yet see the sales from there in the financial statements. Stenocare sells through its partner Weeco, who uses its network. The doctors are still in the training period, which is an advantage for Stenocare, because their product Astrum 10-10 is included in the first wave. My expectations for the doctors in Germany are that they will welcome Astrum 10-10, because the medicine meets all the requirements that doctors have continuously made for medical cannabis, if they are to prescribe prescriptions; these requirements continuously emerged in various articles before Germany released medical cannabis. I have listed these requirements in bullet points, and Stenocare can tick off all the requirements, because Astrum 10-10 meets them all 1. The medicine must have the strength stated on the label in all batches. 2. It must work within the time the manufacturer promises 3. It must meet the strict requirements that Germany demands 4. It must be approved by their insurance companies 5. That there is reimbursement for the medicine 6. That doctors can count on a consistent absorption every time. Therefore, my expectations are that Astrum 10-10 will perform well in Germany, as doctors are trained in the product.·17.4.Germany is irrelevant for StenoCare.
- ·16.4.The USA is further ahead than Europe regarding research into medical cannabis, etc. Therefore, I also find articles about research over there. Researchers have found out. that CBD is better to use as sleep medicine, because people fall asleep and dream. It is commonly known that traditional sleep medicine deprives people of their dreams, which causes some bad side effects. Sleep problems are also a phenomenon outside the USA, personally I know several, and who use CBD oil to fall asleep, they have the same good experience. https://www.nugmag.com/cbd-for-better-sleep-discovering-its-powerful-effects/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 330 | - | - | ||
| 3 000 | - | - | ||
| 2 582 | - | - | ||
| 948 | - | - | ||
| 30 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 32 424 | 32 424 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 32 424 | 32 424 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
2025 Q4 -tulosraportti
Vain PDF
56 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·14 t sittenWill it positively affect stenocare that American cannabis stocks are currently rising a lot?·1 t sitten · MuokattuI don't think so. I would say that it depends on how Stenocare's earnings will be in Germany. The more earnings, the higher the share price. Roughly speaking. To something completely different. First, I just want to say that the German health insurance system is completely bonkers. I coincidentally stumbled upon the fact that there have been changes in their health insurance system in April 2024. These changes are beneficial for the Astrum 10-10 oil. It is incredibly complicated, so the explanation is broadly speaking. Because Astrum 10-10 has a 100% reimbursement approval, it will be easier for the doctor to get permission to prescribe a prescription that will be approved faster than if there is no reimbursement approval. Because Astrum 10-10 has a reimbursement approval, the application does not automatically get fast processing, but the doctor must request it themselves. But for products that do not have any reimbursement approval, it will be almost impossible for the doctor to get fast processing, nor to be allowed to prescribe a prescription. Fast processing when a product meets the above. For terminally ill patients, the doctor can give the prescription to their patients immediately, without the application having to be submitted first. For very ill patients, the doctor can give a prescription to their patients, in 3 days. For all others, it is up to 3 weeks, that is when the doctor assesses that it is urgent for their patients, but they are not terminally ill. Stenocare has stated that the two partners are in full swing teaching the doctors in their network how to fill out an application when it comes to Astrum 10-10, because this is a very complicated process. They have been doing this since 2024. As I wrote, a completely bonkers system.
- ·2 päivää sitten · MuokattuBecause blueoceanguy very aggressively attacks Stenocare and has made claims that Stenocare as a company has no business in Germany, and that they will not make money in Germany, I set out to find articles, or something similar, that would show that Stenocare as a company will indeed make a lot of money in the German market. It has not been a straightforward path; it was very complicated. I found that the German system is completely different from the Danish one, and that the way the German system is structured will actually be an advantage for Stenocare's earnings. What I have found out, I share below, which you can read if it interests you. For clarity, I have put it in bullet points. 1. Astrum 10-10 is approved for 100% reimbursement by two insurance companies (Techniker Krankenkasse and AOK Rheinland, which together have about 14 million members) where the medicine will be free, but in Germany, one apparently pays a prescription fee, from 30-75kr. per prescription. As long as there is 100% reimbursement, and a person has started using Astrum 10-10, and it works as it should, it will be rare for people to switch to another brand. This will provide continuous sales of Astrum 10-10 2. In Germany, public reimbursement is called reimbursement, and this reimbursement will be the primary reason why Astrum 10-10 will become very valuable for Stenocare's earnings. 3. Doctors in Germany are more inclined to prescribe medicine with the highest subsidy than medicine with less than 100% subsidy, because doctors want to ensure that their patients can afford to buy the medicine. 4. But in Germany, doctors have a fixed budget for each quarter for medicine they prescribe to their patients, and which they must adhere to. If doctors only prescribe the most expensive medicine, that is, only medicine that insurance companies have not approved for reimbursement, which would cause doctors to exceed the fixed budget, then the doctors themselves will have to pay the difference out of their own pocket to the public. Astrum 10-10 is approved for 100% reimbursement, so prescribing Astrum 10-10 to their patients will not affect the doctors' budget. This also means that Astrum 10-10 is not price-sensitive in Germany, compared to a product that is not approved for 100% reimbursement. 5. German doctors also consider whether the medicine they prescribe has a positive effect on their patients, and whether the medicine's content complies with what is stated on the label, but also look at whether there is reimbursement, for the reasons mentioned above. 6. In Germany, doctors must write an application for their patients the first time they want to prescribe medicine that is reimbursed. This can be complicated, so Weeco is busy teaching doctors how to correctly write the application. This process also means that doctors will not be keen for their patients to switch to another brand. This is a significant reason why Astrum 10-10 will have a stable income in Germany once the market is saturated. 7. Finally, Germany is considered a growth market, see link below Explanation of telemedical service. At the time of writing, one must appear in person for the first prescription, subsequently within 12 mths., one can call the doctor and get a prescription, and it is forbidden to send flower medicine by post, but pharmacies are allowed to send cannabis oil by post. This point is not yet clarified in Germany. When Stenocare claims that Astrum 10-10 will become very valuable for Stenocare's earnings, I believe that is absolutely correct. Germany is considered a growth market for prescription medical cannabis https://businessofcannabis.com/new-report-uk-and-germany-medical-cannabis-markets-both-double-in-2025/·23 t sittenHm, you yourself have Stenocare, so I think that you have followed along, and therefore are aware that they have had an operating profit for the last 3 quarters. That in 2026 they have two partners in Germany, who have more than 7000 doctors in their network. That both partners are connected to the German distribution platform, which all 18,000 pharmacies use to order medicine. I think there is substance in it, when Stenocare's management has an optimistic attitude towards sales in Germany. Now, it is a management that is very conservative, and therefore you don't get more out of them than that they are optimistic. In addition to this, I have remembered that last year, they divested the cultivation facilities, and the expenses for this are over, as well as the expense that has been for winding these down, will be a one-off expense, therefore these expenses are over, and for all future. This also means that Stenocare stands much stronger now, financially, than when they had the aforementioned expenses. Praise, I would not call it that. Realism I would rather call it.·20 t sittenAt the current stage, it is nothing but praise - that is a fact. And trust me: We know Weeco quite well, and they are a minnow player in the German market. They buy and try to sell all sorts of crap from various distributors they can get in touch with. It is not a partner that moves the needle commercially - it is a partner that at best gives STENOCARE a foot in the door, and at worst fills warehouse shelves without real off-take in the pharmacy channel. So when "strategic partnership" and similar are mentioned in press releases, one should read it with those glasses: it is distribution on trial, not a guarantee of revenue. And until the opposite is proven, this is merely praise and hot air – nothing else.
- ·17.4.I am starting a new thread. I wrote a post as a continuation of another one a little while ago, But it got lost. Astrum 10-10 is being sold through Weecos' network in Germany. Sales started on February 1, 2026. Therefore, we cannot yet see the sales from there in the financial statements. Stenocare sells through its partner Weeco, who uses its network. The doctors are still in the training period, which is an advantage for Stenocare, because their product Astrum 10-10 is included in the first wave. My expectations for the doctors in Germany are that they will welcome Astrum 10-10, because the medicine meets all the requirements that doctors have continuously made for medical cannabis, if they are to prescribe prescriptions; these requirements continuously emerged in various articles before Germany released medical cannabis. I have listed these requirements in bullet points, and Stenocare can tick off all the requirements, because Astrum 10-10 meets them all 1. The medicine must have the strength stated on the label in all batches. 2. It must work within the time the manufacturer promises 3. It must meet the strict requirements that Germany demands 4. It must be approved by their insurance companies 5. That there is reimbursement for the medicine 6. That doctors can count on a consistent absorption every time. Therefore, my expectations are that Astrum 10-10 will perform well in Germany, as doctors are trained in the product.·17.4.Germany is irrelevant for StenoCare.
- ·16.4.The USA is further ahead than Europe regarding research into medical cannabis, etc. Therefore, I also find articles about research over there. Researchers have found out. that CBD is better to use as sleep medicine, because people fall asleep and dream. It is commonly known that traditional sleep medicine deprives people of their dreams, which causes some bad side effects. Sleep problems are also a phenomenon outside the USA, personally I know several, and who use CBD oil to fall asleep, they have the same good experience. https://www.nugmag.com/cbd-for-better-sleep-discovering-its-powerful-effects/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 330 | - | - | ||
| 3 000 | - | - | ||
| 2 582 | - | - | ||
| 948 | - | - | ||
| 30 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 32 424 | 32 424 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 32 424 | 32 424 | 0 | 0 |